Regulatory Catalysts and Launch Readiness for Bezuclasitinib Underpin Sam Slutsky’s Buy Rating on Cogent Biosciences
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Sam Slutsky maintains a Buy rating on Cogent Biosciences with a $55 price target. The recommendation is driven by bezuclasitinib's regulatory catalysts, including upcoming FDA decisions and an filed NDA for advanced SM. Slutsky highlights the company's robust launch readiness, fully staffed commercial teams, and Expanded Access Program. Promising PEAK trial data and ongoing studies suggest broader label potential, reinforcing a constructive outlook on the stock.
Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Cogent Biosciences, with a price target of $55.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Sam Slutsky has given his Buy rating due to a combination of factors related to Cogent Biosciences’ late-stage asset bezuclasitinib and its commercialization readiness. He highlights that the company is approaching key FDA decision dates for bezuclasitinib in second-line GIST and non-advanced systemic mastocytosis, while an NDA for advanced SM has already been filed, creating multiple near-term regulatory catalysts that could unlock substantial value.
Slutsky also emphasizes Cogent’s robust launch preparation and pipeline expansion strategy. The company has fully staffed its commercial and medical field teams and is running an Expanded Access Program in the U.S., which should support early uptake. In addition, promising data from the PEAK trial and ongoing studies in first-line GIST and NonAdvSM “switch” patients point to broader label and revenue upside, reinforcing his constructive view on the stock.